Mar 09, 2019
A multistate, not-for-profit integrated delivery network on the East Coast was concerned about a sharp increase in annual spend for parenteral analgesics but was unsure of the root cause.
Lumere’s web-based Utilization Management solution identified a 30% increase in Ofirmev spend. After reviewing 200+ published journal articles and trials, Lumere recommended that the system remove Ofirmev from its inpatient formulary. Given the drug’s similar efficacy and safety compared to other parenteral analgesics, its clinical benefits did not offset the higher cost.
Lumere analyzed the health system’s data to determine the key surgical physician specialties responsible for the majority of utilization and involve these groups in the decision process. System leaders collaborated with Lumere to further analyze physician-level utilization, review additional evidence and develop a tactical plan to facilitate change.
Removing Ofirmev from formulary will yield a projected $1M+ in annual savings — 54% off a base spend of $2.2M – without negatively impacting clinical quality or patient outcomes.
annual savings in Ofirmev spend
savings in parenteral anelgesics
impact on outcomes
© Lumere All rights reserved